Astal Laboratories Ltd has signed a Letter of Intent (LOI) with Switzerland-based Immuna Therapeutics GmbH to secure exclusive India rights to next-generation CAR-T cell therapies, including TriCAR-T platforms. The partnership aims to localize manufacturing and clinical development, potentially adding ₹300 crore in incremental revenue for Astal.
In a major step toward expanding its presence in advanced therapies, Astal Laboratories Ltd announced a strategic collaboration with Immuna Therapeutics GmbH of Switzerland. Under a newly signed Letter of Intent, Astal gains exclusive India rights to Immuna’s next-generation CAR-T and TriCAR-T technologies.
The partnership aims to establish a localized ecosystem for cell and gene therapy in India, addressing the growing demand for advanced oncology treatments. It will cover technology transfer, clinical trials, and commercialization, building a strong platform for future innovation.
Key Highlights:
-
The collaboration includes technology transfer and local production setup in India.
-
Astal projects incremental revenue of around ₹300 crore post-implementation.
-
Focus areas include next-generation CAR-T and TriCAR-T immuno-oncology therapies.
-
The move aligns with Astal’s long-term strategy to expand into cell and gene therapy segments.
-
The partnership strengthens India’s access to cutting-edge cancer therapies and supports healthcare innovation.
Source: BSE Corporate Announcement